CHANG RONG-KUN has a total of 12 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and micro-structure and nano-technology are DEVIREX AG, SOLVON ARZNEI VERTRIEB LIZENZ and THERANEXUS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Micro-structure and nano-technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Nanostructure applications |
# | Name | Total Patents |
---|---|---|
#1 | Chang Rong-Kun | 12 |
#2 | Shah Niraj | 6 |
#3 | Raoufinia Arash | 4 |
#4 | Burnside Beth A | 1 |
#5 | Couch Richard A | 1 |
#6 | Huang Austin B | 1 |
#7 | Patel Sachin V | 1 |
#8 | Vieira Michael L | 1 |
#9 | Bhatt Padmanabh P | 1 |
#10 | Liang Likan | 1 |
Publication | Filing date | Title |
---|---|---|
WO2006044805A2 | Less abusable pharmaceutical preparations | |
WO2004096125A2 | Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem | |
WO2004069187A2 | Drug formulation and delivery using crystalline methylated cyclodextrins | |
WO2004062577A2 | Two or more enteric materials to regulate drug release | |
US8906413B2 | Drug formulations having reduced abuse potential |